NDAQ:HOTH - Post Discussion
Post by
Iseneschal on Jan 18, 2024 8:34am
HOTH.....NR this a.m....LFG!
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
2024-01-18 05:20 PT - News Release
Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics
NEW YORK, Jan. 18, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001, which is being developed as a potential treatment for cancer patients undergoing treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI). The trial is being conducted under Hoth's open Investigational New Drug Application (IND) for HT-001.
Be the first to comment on this post